Tiviciclovir
Alternative Names: S-2242Latest Information Update: 18 Feb 2000
Price :
$50 *
At a glance
- Originator Aventis
- Class Antivirals; Nucleosides; Small molecules
- Mechanism of Action DNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cytomegalovirus infections
Most Recent Events
- 18 Feb 2000 No-Development-Reported for Cytomegalovirus infections in Belgium (Unknown route)
- 18 Feb 2000 No-Development-Reported for Herpesvirus infections in European Union (Unknown route)
- 29 Dec 1999 Hoechst Marion Roussel has merged with Rhône-Poulenc Rorer to form Aventis Pharma